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1. Introduction 
Cyclic nucleotides (CAMP, cGMP) act as second 
messengers in a number of biochemical reactions 
which support homeostasis in the living animal [ 1,2] . 
Our recent reports show that fusidic acid, a steroidal 
antibiotic which inhibits in vitro protein synthesis: 
(i) Stimulates the in vivo incorporation of ammo 
acids into proteins of rat liver, kidney, brain and 
muscle [3] . 
(ii) Enhances the in vivo uptake of “Pi into the liver 
intracellular phosphate pool. 
(iii) Stimulates the in vivo phosphorylation of proteins 
in all cell fractions of the rat liver except mito- 
chondria [4] . 
(iv) Significantly increases blood glucose concentra- 
tions. 
These observations suggest he involvement of cyclic 
nucleotides in the action of fusidic acid on protein 
synthesis and gluconeogenesis and/or glycogenolysis. 
We have determined that fusidic acid increases the 
concentration of blood CAMP while simultaneously 
lowering the blood cGMP concentration in the intact 
rat. Concentrations of these cyclic nucleotides remain 
unchanged in liver, kidney and muscle. There is an 
increase in blood glucose which is positively correlated 
with the change in blood CAMP concentration. Altera- 
tion of kidney function through bilateral nephrectomy 
or ureteral ligation tended to increase blood concen- 
trations of both CAMP and cGMP. When nephrecto- 
mized or ureter-ligated rats were treated with fusidic 
acid there was an increase in the concentration of 
CAMP and a reduction in cGMP in the blood similar 
to that observed in fusidic acid treated intact rats. 
In contrast to the failure of fusidic acid to alter 
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tissue concentrations in intact or nephrectomized rats, 
fusidic acid treatment of ureter-ligated rats caused a 
reduction in liver and muscle cyclic nucleotide con- 
centrations and an increase in kidney cyclic nucleo- 
tide concentrations. Alteration of kidney function 
failed to inhibit the stimulation of labelled amino 
acid incorporation into protein by fusidic acid 
(unpublished data, E. Z., P. Gachon, F. W. S.). 
2. Materials and methods 
Female Sprague-Dawley rats, weighing 165-l 80 g 
were fed Purina Rat Chow ad libitum. Bilaterial 
ureteral ligations, nephrectomy and sham operations 
of both surgical procedures were performed under 
ether anesthesia. Sham operations had no effect on 
the results of the experiments. Rats with altered 
kidney function were used for experiments when 
their blood urea concentration exceeded 225 mg/dl; 
12 h post-nephrectomy and 18 h post-ureteral ligation. 
Rats were injected i.p. with 0.5 ml saline or saline 
containing 10 mg sodium fusidate (a gift from W. 0. 
Godtfredsen and W. von Daehme, Leo Pharmaceutical 
Products, Ballerup, Denmark). At arbitrarily deter- 
mined times rats were decapitated as noted in fig.1 
and tables 1,2; Blood (1.98 ml) was collected into ice 
cold tubes containing 20 d 0.5 M EDTA (pH 7.5 
with 1 M NaOH) and vortexed, then extracted with 
ethanol. The ethanolic extract was evaporated to 
dryness in a Buchler Rotary Evapo-Mix. The dry 
precipitates were stored at 5’C until used for assay. 
Livers, kidneys and a portion of the gastrocnemius 
and soleus muscles from each hind limb were removed 
immediately, frozen between liquid N2 pre-cooled 
219 
Volume 86, number 2 FEBS LETTERS February 1978 
blocks and stored under liquid Nz until assayed. rats (table 1). In a separate experiment, blood urea 
Tissue samples were homogenized in 4 mM EDTA concentration did not change significantly (P > .05) 
and deproteinized by heating in a boiling water bath over a 60 min period after fusidic acid administration 
for 5 min. i.p. to intact rats (not shown). 
Cyclic nucleotides were measured with Amersham’s 
cyclic GMP RIA KIT and cyclic AMP RIA KIT 
(several kits were gifts of N. Magit, Amersham, 
Arlington, IL). 
Blood glucose and urea were measured by the 
glucose-oxidase-peroxidase method and the urease- 
Berthelot method of Boehringer-Mamrhein, Indiana- 
polis, IN, respectively. 
All other chemicals and reagents were of the 
highest purity commercially available. 
In fed intact rats, fusidic acid administration 
resulted in an increase in blood glucose concentration 
which remained elevated for at least 40 min (tig.1). 
This increase was also observed in 24 h starved rats. 
(A t 59 mg/dl glucose, not shown.) Ureteral ligation 
had little effect on blood glucose concentrations, but 
nephrectomy reduced blood glucose by nearly 33% in 
fed rats (table 1). Neither of these alterations of 
kidney function affected the fusidic acid-induced 
elevation in blood glucose concentration, in fact, it 
was more effective (1 .O-fold) in these rats than in 
intact rats. 
3. Results and discussion 
Removal of various endocrine glands did not alter 
the fusidic acid-induced incorporation of labelled 
amino acid into protein [3]. The kidney has been 
shown to be one of the sites for molecular alteration 
of vitamin D, a sterol, in the formation of an active 
metabolite [5] . Similarities in molecular structure 
between fusidic acid and vitamin D suggest hat 
kidney function may also play a role in the in vivo 
effect of fusidic acid. Surgery was timed so that 
blood urea concentrations in the rats were similar, 
after nephrectomy or ureteral ligation, just prior to 
fusidic acid administration. Fusidic acid did not 
significantly affect blood urea concentrations 
(P > .05) in intact, ureter-ligated or nephrectomized 
The in vivo effect of fusidic acid administration on 
blood glucose concentration may be due to either 
increased glycogenolysis and/or gluconeogenesis. In 
the intact fed rat, 20 min post-fusidic acid aministra- 
tion, blood concentration of CAMP was increased 
more than 2.7-fold and cGMP was reduced by more 
than 25% (table 1). As shown in fig.1, the change in 
CAMP concentration (2-fold) occurred concomitant- 
ly with the elevation in blood glucose concentration. 
Cyclic AMP remained elevated throughout the 60 min 
period. These in vivo effects of fusidic acid administra- 
tion on blood CAMP concentration may be mediated 
via glucagon [6] or catecholamines [7,8]. However, 
catecholamine administration has been reported to 
increase blood and urinary cGMP concentration [9]. 
Therefore, the observed decrease in cGMP blood 
Table 1 
The effect of fusidic acid in vivo on the concentration of blood glucose, urea and cyclic nucleotides in the fed rata 
No. rats Glucose Urea CAMP cGMP cAMP/cGMP 
(mgldl) (mg/dl) (pmol/mD (pmol/ml) 
Sal&I 
Intact 4 150 f 2.8b 52 + 2.3 21.4 f 3.7 20.5 * 2.3 1.1 f 0.15 
Ureter-ligated 4 137 f 9.3 312 * 13.1 34.7 r 2.9 32.4 * 4.3 1.1 f 0.12 
Nephrectomized 4 108 r 2.4 234 + 13.5 49.7 * 8.6 30.1 f 7.0 1.9 f 0.43 
Fusidic 
Intact 3 218 f 39.1 58 f 2.3 56.6 f 10.6 14.6 f 1.9 4.1 f 1.19 
Ureter-ligated 5 239 + 20.8 296 f 10.1 83.1 f 14.7 7.1 f 0.4 11.7 ?: 1.89 
Nephrectomized 4 195 f 18.8 261 f 6.5 77.2 i. 11.2 14.0 i 2.2 5.6 i 0.19 
a Determined 20 min after fusidic acid injection 
b Values f standard error of the mean 
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Fig. 1. The effect of fusidic acid in vivo on the kinetics of 
blood glucose, CAMP and cCMP concentrations in the fed 
intact rat. Treatment, ime, number of animals in parenthesis 
and standard error of the mean are as follows: 
No injection, zero time (2): glucose f 1.0 mg/dl; CAMP f 3.0 
pmol/ml; oGMP f 0.1 pmol/ml. 
Saline injection, after 5 min (7), 10 min (lo), 20 min (4), 
40 min (4) and 60 min (4) glucose f 6.7,6.8,3.9,2.7 and 
17.6 mg/dl; CAMP * 10.1, 10.1, 10.7,5.2 and 5.5 pmol/ml; 
cCMP f 2.2, 1.1, 1.8,3.3 and 8.1 pmol/ml;respectively. 
Fusidic acid injection, after 5 min (6), 10 min (8), 2q min (4), 
40 min (4) and 60 min (4): glucose f 8.3,8.1, 22.4,7.8 and 
13.0 mg/dl; CAMP f 4.9,8.5, 33.6, 18.0 and 11.0 pmol/ml; 
cGMP f 0.7,0.8,4.5,0.6 and 3.1 pmol/ml; respectively. 
concentration would suggest hat fuaidic acid does 
not act via catecholamines. While cAMP/cGMP in 
the blood was also increased nearly 4-fold, no signifi- 
cant change (P > .OS) could be detected in liver, 
kidney or muscle CAMP and cGMP concentrations or 
ratios. Under the influence of ghrcagon, the liver 
apparently is the major source of blood CAMP [lo]. 
Our data confirm those of [ 1 l] (perfused liver) and 
[ 121 (infused intact rat) where increases in blood 
concentrations of CAMP and glucose without a 
detectable change in liver nucleotide concentration 
are reported. Our data also support the findings of 
[13] where, under basal conditions, much of the 
CAMP of the liver is metabolically inert and not freely 
diffusable because of binding or sequestration. Our 
data are the first to show that steroidal molecules, 
other than glucocorticoids, can affect blood CAMP 
and glucose concentrations. 
Five minutes after fusidic acid administration to 
the intact rat (fig.1) there was a transient reduction 
in blood cGMP concentration which returned to 
control level by 20 mm. However by 40 min, blood 
cCMP concentration had decreased to approx. 50% 
of the saline control rats and remained depressed 
throughout the remainder of the experiment. Blood 
cyclic GMP concentrations in the fusidic acid-treated 
rats were reduced below control concentrations at 
20 min in the experiment shown in table 1. The small 
intestine has been suggested as the source of the 
major portion of cGMP found in the blood [ 141. 
The reduction in blood concentration of cGMP could 
be due to an inhibition in the release of cGMP from 
the intestine by fusidic acid. In addition, the rate of 
blood cGMP excretion or metabolic degradation by 
the kidney may have increased [10,14]. However, 
our results obtained from rats with altered kidney 
function refute this latter viewpoint (table 1) and 
will be discussed later. 
The kidney has been shown to remove blood 
CAMP and cGMP via glomerular filtration [lo] . This 
fact is supported by the increase in blood CAMP 
(2-fold) and cGMP (1 S-fold) after ureteral ligation 
and nephrectomy. Ureteral ligation also elevated 
CAMP concentration 1 S-fold in the liver and reduced 
CAMP by 50% in the kidney (table 2). There was also 
a 2-fold increase in cGMP concentration in both liver 
and kidney of the ureter-ligated rat. Only the liver 
concentration of cGMP was increased (1 S-fold) in 
the nephrectomized rat. 
Neither of the alterations of kidney function 
suppressed the nearly 2-fold stimulation of blood 
CAMP concentration by the administration of fusidic 
acid. Fusidic acid was slightly more effective in lower- 
ing blood cGMP concentration in the nephrectomized 
rat than in the intact rat. However, fusidic acid was 
much more effective in regard to lowering blood 
cGMP concentrations in ureter-ligated rats. This 
reduction in blood cGMP concentration is a reflec- 
tion of the ability of fusidic acid to inhibit tissue 
release of cGMP. 
Kidney glomerular filtration and excretion [lo] 
might also be increased under the influence of fusidic 
acid, which would account for the increase in kidney 
concentration of cGMP (1.7-fold) and CAMP (1.6-fold) 
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in the ureter-ligated rat (table 2). Alternatively, the 
inability to eliminate urine from the kidney might 
inhibit only the metabolic degradation of cyclic 
nucleotides. Of the tissues assayed, only muscle 
CAMP concentration was reduced by 25%. This 
increase in urinary excretion of cGMP may also have 
occurred when fusidic acid was administered to the 
intact rat, however we did not determine urinary 
cyclic nucleotides: If the kidney excretion rate of 
blood cyclic nucleotides was the only point of control 
of fusidic acid, then the nephrectomized rat should 
have exhibited an elevated blood cGMP concentration 
which was not the case. This shift in tissue concentra- 
tions of cyclic nucleotides in the ureter-ligated rat 
under the influence of fusidic acid was not observed 
in intact or nephrectomized rats (table 2). Apparently 
the kidney becomes a ‘sink’ for cyclic nucleotides 
when excretion or metabolic degradation is inhibited 
by fusidic acid administration to the ureter-ligated 
rat. 
Cyclic GMP has been suggested as a stimulator of 
polypeptide synthesis [20] , since rat liver EF-2 has 
guanyl cyclase activity and may be involved in the 
conversion of GTP to cGMP. In vitro experiments 
have shown that fusidic acid blocks functions depen- 
dent on EF-2 and a specific eukaryotic ribosome- 
independent GTPase which is distinct from EF-2 
[21]. Although we have also observed an early inhibi- 
tion in the incorporation of labelled leucine into 
isolated hepatocytes, protein synthesis is apparently 
released from this inhibition as the incubation time 
progresses (unpublished data, E.Z., F.W.S.). However, 
free polyribosomes isolated from livers of rats admin- 
istered fusidic acid in vivo were nearly twice as active 
in an in vitro protein synthesizing system as those 
from livers of controls (unpublished data, F. W. S., 
A. A. Hochberg). 
Several reports have indicated that steroids such as 
estrogen can increase cGMP concentration in the 
uterus which the authors attributed to a reduction 
in cGMP phosphodiesterase, whereas progesterone 
inhibits the increase in cGMP [ 161. Furthermore, 
other steroids, such as glucocorticoids, increase 
urinary excretion of cGMP with a concomitant 
decrease in the concentration in the lung [ 17,I 81. 
The effect of glucocorticoids is difficult to interpret, 
since in adrenalectomized rats the hepatic concentra- 
tion of cGMP was decreased and skeletal muscle con- 
centration increased while both tissues exhibited 
increased guanyl cyclase and cGMP phosphodiesterase 
activity [ 191 . 
The in vivo stimulation of the incorporation of 
labelled leucine into tissue proteins (anabolic processes) 
by fusidic acid [3] could be attributed to an increase 
in the cGMP concentration at the site(s) of poly- 
peptide (protein) synthesis. This is reflected by the 
decrease in blood cGMP concentration. This increased 
incorporation is more rapid than can be accounted for 
by increased in vitro DNA synthesis as a result of ele- 
vated concentrations of CAMP [ 1.51. Modification of 
cell membrane release or transport by fusidic acid 
could be a method of control which determines the 
level of ‘active’ cGMP at the site(s) of polypeptide 
synthesis. This would not necessarily involve detect- 
able increases or decreases in guanyl cyclase activity 
or tissue cGMP concentration which may be ‘physio- 
logically unnecessary’. 
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